Biotechnology company Alveus Therapeutics has raised $159.8 million to advance its next-generation therapies for obesity and metabolic diseases.  Proceeds from the Series A financing will support Phase II clinical development of ALV-100, the company’s lead programme, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.  ALV-100 is a bifunctional […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!